6 RESULTS
COMMENT I agree with the cautions by others that care must be taken not to let the new framework influence clinical practice until it is validated for that purpose. I’m sure that the authors will be the first to agree, but enforcing that might be difficult. The ...
COMMENT The recently published Fourth Report of the DLB Consortium, which updated recommendations about DLB diagnosis and management, prioritized “strategies to progress critical areas of biological research, include collecting samples from large population-based ...
COMMENT This paper is carefully modest in its claims, as one would expect from this very expert group of clinical researchers who understand well the complexities of FTD. The identification of a significant subset (36 percent) of bvFTD patients with primarily ...
COMMENT This development will be welcomed by people with PD and psychosis and their families, and by clinicians who struggle to manage such symptoms and who find themselves resorting to treatments of limited effectiveness but significant toxicity. The question ...
COMMENT Little is known about the mutual trajectories of α-synuclein and Aβ accumulation in vivo in humans. Longitudinal imaging studies do not yet exist. We recently examined the clinical phenotype (cognitive fluctuation, recurrent visual hallucinations, ...
COMMENT Reply to Chirco Laurie There isn't any systematic information about age of onset of DLB, but the situation is probably similar to Alzheimer disease, i.e., that young onset does occur although is relatively uncommon. The sparse literature suggests ...
